Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business Highlights

Rhea-AI Summary

Aldeyra Therapeutics (Nasdaq: ALDX) will hold a conference call on March 11, 2021, at 8:00 a.m. ET to discuss its financial results for the year ending December 31, 2020, along with business highlights. Interested parties can join via dial-in or through a live webcast available on the company’s Investors & Media page. Aldeyra is a clinical-stage biotech company focused on developing therapies targeting immune-mediated diseases, with key compounds in clinical trials for conditions such as dry eye disease and COVID-19.

Positive

• Aldeyra's investigational compound reproxalap is in Phase 3 trials for dry eye disease, indicating significant progress in clinical development.
• The company has a diverse clinical pipeline, including treatments for systemic inflammatory diseases and COVID-19, suggesting potential for future revenue growth.

Negative

• None.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, March 11, 2021 to report financial results for the year ended December 31, 2020 and discuss recent business highlights.

The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 6253616. A live webcast of the conference call will also be available on the Investors & Media page of the company’s corporate website at https://ir.aldeyra.com.

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005055/en/

FAQ

What are Aldeyra Therapeutics' latest financial results?

Aldeyra will report its financial results for the year ended December 31, 2020, on March 11, 2021.

When is Aldeyra's conference call scheduled?

The conference call is scheduled for March 11, 2021, at 8:00 a.m. ET.

What is the status of Aldeyra's clinical trials?

Aldeyra's lead compound reproxalap is currently in Phase 3 clinical trials for dry eye disease and allergic conjunctivitis.

What is the purpose of Aldeyra's conference call on March 11, 2021?

The conference call will discuss the company's financial results and recent business highlights.